



STEROIDAL SAPONINS FROM THE STEMS OF *DRACAENA CONCINNA*

YOSHIHIRO MIMAKI,* MINPEI KURODA, YOKO TAKAASHI and YUTAKA SASHIDA*

School of Pharmacy, Tokyo University of Pharmacy and Life Science, Horinouchi 1432-1, Hachioji, Tokyo 192-03, Japan

(Received in revised form 21 July 1997)

Key Word Index—*Dracaena concinna*; Agavaceae; stems; steroidal saponins; furostanol saponins; spirostanol saponins.

Abstract—A total of thirteen steroidal saponins, including four new furostanol saponins, were isolated from the fresh stems of *Dracaena concinna*. The structures of new saponins were determined by detailed analysis of their ^1H and ^{13}C NMR spectra, hydrolysis, and by comparison of spectral data of known compounds. Two of the new furostanol saponins are unique in structure possessing a 4α -hydroxyl group on the furostanol skeleton.
© 1998 Elsevier Science Ltd. All rights reserved

INTRODUCTION

The family Agavaceae with more than 480 species has a distribution in the tropic and subtropic dry climate regions throughout the world. The occurrence of steroidal saponins in several Agavaceae plants is well documented [1, 2]. We have already made phytochemical screening of the three Agavaceae plants, *Nolina recurvata* [3–5], *Sansevieria trifasciata* [6, 7] and *Cordyline stricta* [8, 9], and isolated a variety of new steroidal saponins and pregnane glycosides.

As part of our program of the chemical investigation of Agavaceae plants, we have now examined the fresh stems of *Dracaena concinna* which is native to Mauritius and cultivated as an excellent foliage plant. This study has resulted in the isolation of a total of thirteen steroidal saponins, including four new furostanol saponins. This paper describes the structural determination of the four new furostanol saponins by detailed analysis of their ^1H and ^{13}C NMR spectra, hydrolysis, and by comparison of spectral data of known compounds.

RESULTS AND DISCUSSION




The 1-butanol-soluble phase of the methanolic extract of *D. concinna* stems was chromatographed on Diaion HP-20 and silica gel to give saponin fractions. Each fraction was subjected to silica gel and octadecylsilanized (ODS) silica gel column chro-

matography, and to preparative HPLC to furnish compounds 1–13.

Compounds 1–9 were known steroidal saponins and identified as (25*R*)-spirost-5-ene-3 β -ol (diosgenin) 3-*O*-{*O*- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-*O*-[α -L-rhamnopyranosyl-(1 $\rightarrow$ 4)]- β -D-glucopyranoside} (1) [10], diosgenin 3-*O*-{*O*- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-*O*-[β -D-glucopyranosyl-(1 $\rightarrow$ 3)]- β -D-glucopyranoside} (2) [11], (25*R*)-spirost-5-ene-1 β ,3 β -diol (ruscogenin) 1-*O*-{*O*- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)- α -L-arabinopyranoside} (3) [12], ruscogenin 3-*O*-{*O*- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-4-*O*-sulfo- α -L-arabinopyranoside} (4) [13], (23*S*,24*S*,25*S*)-spirost-5-ene-1 β ,3 β ,23,24-tetrol 1-*O*-{*O*- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-*O*-[β -D-xylopyranosyl-(1 $\rightarrow$ 3)]- α -L-arabinopyranoside} (5) [14], (23*S*,24*S*,25*S*)-spirost-5-ene-1 β ,3 β ,23,24-tetrol 1-*O*-{*O*- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-*O*-[β -D-xylopyranosyl-(1 $\rightarrow$ 3)]- α -L-arabinopyranoside} 24-*O*- β -D-fucopyranoside (6) [14], 26-*O*- β -D-glucopyranosyl-22-*O*-methyl-(25*R*)-furost-5-ene-3 β ,22 ξ ,26-triol 3-*O*-{*O*- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-*O*-[α -L-rhamnopyranosyl-(1 $\rightarrow$ 4)]- β -D-glucopyranoside} (7) [15], 26-*O*- β -D-glucopyranosyl-22-*O*-methyl-(25*R*)-furost-5-ene-3 β ,22 ξ ,26-triol 3-*O*-{*O*- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-*O*-[β -D-glucopyranosyl-(1 $\rightarrow$ 3)]- β -D-glucopyranoside} (8) [16] and 26-*O*- β -D-glucopyranosyl-22-*O*-methylfurosta-5,25(27)-diene-1 β ,3 β ,22 ξ ,26-tetrol 1-*O*-{*O*- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-*O*-[β -D-xylopyranosyl-(1 $\rightarrow$ 3)]- β -D-fucopyranoside} (9) [9], respectively.

Compound 10 ($\text{C}_{46}\text{H}_{76}\text{O}_{18}$) was obtained as an amorphous solid, $[\alpha]_{\text{D}} -45.0^\circ$ (methanol). Its ^1H NMR spectrum in pyridine- d_5 showed signals for three steroid methyls at δ 1.25 (s), 1.11 (d, $J = 6.8$ Hz) and

* Authors to whom correspondence should be addressed.





0.85 (s), an exomethylene group at δ 5.34 and 5.05 (each *br s*), and three anomeric protons at δ 6.41 (*br s*), 4.91 (*d*, $J = 7.8$ Hz) and 4.73 (*d*, $J = 7.7$ Hz). A positive colour reaction in Ehrlich's test [17, 18] and the characteristic ¹H and ¹³C NMR signals at δ_H 3.25 (3H, s), and δ_C 112.4 (C) and 47.3 (Me) [19] were in favour of a 22-methoxyfurostanol saponin. On enzymatic hydrolysis of **10** with β -glucosidase, it liberated glucose to give the corresponding spirostanol saponin (**10a**). Acid hydrolysis with M hydrochloric acid in dioxane-H₂O (1:1) gave a steroidal sapogenin (C₂₇H₄₂O₄) (**10b**), identified as 5 α -spirost-25(27)-ene-1 β ,3 α -diol (1 β -hydroxycrabbogenin) [9, 20], together with D-glucose, D-fucose and L-rhamnose in a ratio of 1:1:1. The ¹H NMR spectrum of **10a** exhibited two anomeric proton signals at δ 6.42 (*br s*) and 4.73 (*d*, $J = 7.8$ Hz). Attempted assignment of the ¹³C NMR signals arising from the saccharide moiety of **10a** by referring to those of the reported saponins [12, 14, 19] indicated the presence of a terminal α -L-rhamnopyranosyl unit and a 2-substituted β -D-fucopyranosyl unit in the molecule of **10a**, leading to the identification of the diglycoside as O- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O- β -D-fucopyranose. This diglycoside was shown to be linked to the aglycone C-1 hydroxyl group by comparison of the ¹³C NMR spectrum of **10a** with that of **10b**: the signal due to the

aglycone C-1 was shifted to a lower field by 7.0 ppm, whereas the signal due to C-2 was moved to a higher field by 5.8 ppm by O-glycosylation. Thus, the structure of **10** was characterized as 26-O- β -D-glucopyranosyl-22-O-methyl-5 α -furost-25(27)-ene-1 β ,3 α ,22 ξ ,26-tetrol 1-O-{O- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O- β -D-fucopyranoside}.

Compound **11** (C₄₅H₇₄O₁₈) was suggested to be a furostanol saponin closely related to **10** from its spectral properties. Enzymatic hydrolysis of **11** with β -glucosidase gave the corresponding spirostanol saponin (**11a**) and glucose, and acid hydrolysis with M hydrochloric acid gave **10b**, together with D-glucose, L-arabinose and L-rhamnose in a ratio of 1:1:1. Analysis of the ¹H and ¹³C NMR spectra of **11a** confirmed that the diglycoside attached to C-1 of the aglycone corresponded to that of **3**. The structure of **11** was formulated as 26-O- β -D-glucopyranosyl-22-O-methyl-5 α -furost-25(27)-ene-1 β ,3 α ,22 ξ ,26-tetrol 1-O-{O- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O- α -L-arabinopyranoside}.

Compound **12** (C₄₆H₇₆O₁₉) had one more oxygen atom than did **10**. Enzymatic hydrolysis of **12** with β -glucosidase gave the corresponding spirostanol saponin (**12a**) and glucose. The whole ¹³C NMR shifts of **12** featured quite a similarity to those of **10** with exceptions of the signals due to the A and B ring carbons. The methylene carbon signal at δ 37.4 assignable to C-4 in **10** was replaced by the oxymethine signal at δ 69.9 in **12**, accompanied by downfield or upfield shifts of the signals due to C-3, C-5 and C-6 by +5.3, +6.2 and -5.7 ppm, respectively; all other



signals, including those due to the saccharide moieties, were almost identical between **12** and **10**. Furthermore, tracing out the proton coupling systems from the 1-H signal through spin-decoupling experiment in the ^1H NMR spectrum allowed the sequential assignment of the protons of the A-ring part, giving rise to the partial structure possessing oxygen atoms at C-1, C-3 and C-4. The above ^{13}C and ^1H NMR data were consistent with the presence of an additional hydroxyl group at C-4. The ^{13}C NMR signal due to C-19 at δ 9.0 was in good agreement with that of **10**, giving evidence for the A/B *trans* (5 α -H) ring junction. The orientation of the oxygen atoms were located as 1 β -equatorial, 3 α -axial and 4 α -equatorial, respectively, by the following ^1H NMR parameters. The H-1 proton observed at δ 4.49 as a *dd* signal coupled to H-2 β (ax) (δ 2.29) with a large *J* value of 11.7 Hz and to H-2 α (eq) (δ 2.63) with *J* = 4.1 Hz. The H-4 proton resonated at δ 3.75 and coupled to H-3 (δ 4.30) with *J* = 2.5 Hz and H-5 (δ 2.00) with *J* = 10.9 Hz. Accordingly, the structure of **12** was assigned as 26-*O*- β -D-glucopyranosyl-22-*O*-methyl-5 α -furost-25(27)-ene-1 β ,3 α ,4 α ,22 ξ ,26-pentol 1-*O*-{*O*- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-*O*- β -D-fucopyranoside}.

Compound **13** ($\text{C}_{46}\text{H}_{76}\text{O}_{19}$) had the same molecular formula as **12**. Its ^{13}C NMR spectrum indicated also the presence of a C-4 hydroxyl group and was suggestive of the stereoisomer of **12** with respect to the orientation(s) of the C-3 and/or C-4 hydroxyl group(s). Spin-decoupling experiments revealed that the H-4 proton at δ 3.73 coupled to H-3 (δ 3.87) and H-5 (δ 1.28) with large *J* values of 12.9 and 9.8 Hz, respectively, and that, in turn, the H-3 proton coupled to H-2 β (ax) (δ 2.34) with *J* = 12.9 Hz. The above data indicated the 3 β -equatorial and 4 α -equatorial orientations of the hydroxyl groups. The H-1 and H-5 protons of **13** were shifted to upper fields by 0.44 and 0.72 ppm, respectively, as compared with those of **12**. This phenomenon was considered to be due to the absence of the 1,3-diaxial interactions between the C-3 hydroxyl group and the H-1 α (ax) and H-5 α (ax) protons in **13**, consistent with the β -equatorial orientation of the C-3 hydroxyl group. The structure of **13** was established as 26-*O*- β -D-glucopyranosyl-22-*O*-methyl-5 α -furost-25(27)-ene-1 β ,3 β ,4 α ,22 ξ ,26-pentol 1-*O*-{*O*- α -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-*O*- β -D-fucopyranoside}.

Compounds **10**–**13** are new furostanol saponins, among which **12** and **13** are unique in structure possessing a 4 α -hydroxyl group on the furostanol skeleton.

EXPERIMENTAL

General. NMR (ppm, *J* Hz): Bruker AM-400, 400 MHz for ^1H NMR. CC: silica gel (Fuji-Silysia Chemical), ODS silica gel (Nacalai Tesque) and Diaion HP-20 (Mitsubishi-Kasei). TLC: precoated Kieselgel 60 F₂₅₄ (0.25 mm thick or 0.5 mm thick, Merck) and RP-18 F₂₅₄S (0.25 mm thick, Merck).

HPLC: a Tosoh HPLC system (pump, CCPM; controller, CCP controller PX-8010; detector, UV-8000 or RI-8010) equipped with a CAPCELL PAK C₁₈ column (Shiseido, 10 mm i.d. $\times$ 250 mm, ODS, 5 μm) for prep. HPLC and a TSK-gel ODS-Prep column (Tosoh, 4.6 mm i.d. $\times$ 250 mm, ODS, 5 μm) for analytical HPLC.

Plant material. *D. concinna* was purchased from Exotic Plants Co Ltd, Japan, and the plant specimen is on file in our laboratory.

Extraction and isolation. The plant material (leaves, fresh weight 11.5 kg) was extracted with hot MeOH (20 l $\times$ 2). The MeOH extract was concd under red. pres. and the viscous concentrate (900 g) was partitioned between H₂O and *n*-BuOH. The *n*-BuOH-soluble phase (420 g) was passed through a Diaion HP-20 column with increasing amounts of MeOH in H₂O. The 80% MeOH and MeOH eluate frs were combined and chromatographed on silica gel eluting with a stepwise gradient mixture of CHCl₃-MeOH (9:1; 4:1; 2:1) and, finally, with MeOH. Frs with the same TLC profile were combined. Five frs (I–V) were recovered. Frs III–V mainly contained steroidal saponins. Fr. III was subjected to silica gel CC eluting with CHCl₃-MeOH (5:1; 4:1; 3:1) and ODS silica gel CC with MeOH-H₂O (17:3; 4:1) to give **5** (48.7 mg), and **1** and **3** with a few impurities. Final purification of **1** was established by prep. HPLC using MeOH-H₂O (9:1), and that of **3** by prep. TLC developing with CHCl₃-MeOH-H₂O (30:10:1) to yield **1** (328 mg) and **3** (48.4 mg), respectively, as pure compounds. Fr. V was further fractionated by subjecting it to ODS silica gel CC with MeOH-H₂O (7:3) into four frs V(a)–V(d). Fr. V(b) was chromatographed on silica gel eluting with CHCl₃-MeOH-H₂O (20:10:1) to yield **8** (43.0 mg). Fr. Vc was subjected to a silica gel column eluting with CHCl₃-MeOH-H₂O (25:10:1) to yield **7** (300 mg). Fr. Vd was subjected to silica gel CC eluting with CHCl₃-MeOH (4:1) and ODS silica gel CC with MeOH-H₂O (7:3; 3:2) and MeCN-H₂O (1:3; 1:4) to collect **4** (123 mg), **2** and **9** with a few impurities, a mixture of **12** and **13**, and a mixture of **6**, **10** and **11**. Purification of **2** and **9** was achieved by means of prep. HPLC using MeOH-H₂O (9:1) for **2** and MeCN-H₂O (1:3) for **9** to furnish **2** (55.3 mg) and **9** (39.4 mg), respectively. Separation of **12** and **13** was carried out by prep. HPLC using MeCN-H₂O (1:4) to yield **12** (47.2 mg) and **13** (22.0 mg). The mixture of **6**, **10** and **11** was subjected to prep. HPLC using MeCN-H₂O (1:3) to result in the isolation of **6** (39.3 mg), **10** (170 mg) and **11** (87.6 mg) as pure compounds.

The physical and spectral characteristics of **1**–**9** were consistent with those previously reported. Data refer to the literature shown in the text.

Compound 10. Amorphous solid. $[\alpha]_D^{27}$ –45.0° (MeOH; *c* 0.12). Negative-ion FAB-MS *m/z* 915 [M–H][–]. IR $\nu_{\text{max}}^{\text{KBr}}$ cm^{–1}: 3420 (OH), 2920 (CH). ^1H NMR (pyridine-*d*₅): δ 6.41 (1H, *br s*, 1'-H), 5.34 and 5.05 (each 1H, *br s*, 27-H₂), 4.91 (1H, *d*, *J* = 7.8 Hz, 1''-H), 4.73 (1H, *d*, *J* = 7.7 Hz, 1'-H), 3.25 (3H, *s*,

OMe), 1.75 (3H, *d*, *J* = 6.1 Hz, 6''-Me), 1.45 (3H, *d*, *J* = 6.3 Hz, 6'-Me), 1.25 (3H, *s*, 19-Me), 1.11 (3H, *d*, *J* = 6.8 Hz, 21-Me), 0.85 (3H, *s*, 18-Me).

Enzymatic hydrolysis of 10. Compound **10** (16 mg) was treated with β -glucosidase (20 mg) in HOAc-NaOAc buffer (pH 5, 5 ml) at room temp. for 12 hr. The reaction mixture was chromatographed on silica gel eluting with CHCl₃-MeOH-H₂O (25:10:1) to give the corresponding spirostanol saponin (**10a**) (4.0 mg) and glucose (1.9 mg).

Compound 10a. Amorphous solid. $[\alpha]_D^{25} -28.1^\circ$ (MeOH; *c* 0.14). Negative-ion FAB-MS *m/z* 721 [M-H]⁻. IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3410 (OH), 2920 (CH). ¹H NMR (pyridine-*d*₅): δ 6.42 (1H, *br s*, 1''-H), 4.80 and 4.77 (each 1H, *br s*, 27-H₂), 4.73 (1H, *d*, *J* = 7.8 Hz, 1'-H), 1.77 (3H, *d*, *J* = 6.1 Hz, 6''-Me), 1.45 (3H, *d*, *J* = 6.3 Hz, 6'-Me), 1.26 (3H, *s*, 19-Me), 1.03 (3H, *d*, *J* = 6.9 Hz, 21-Me), 0.88 (3H, *s*, 18-Me). Glucose was identified by direct TLC comparison with an authentic sample. *R_f* (*n*-BuOH-Me₂CO-H₂O, 4:5:1): 0.34.

Acid hydrolysis of 10. A soln of **10** (20 mg) in M HCl (dioxane-H₂O, 1:1, 4 ml) was heated at 100°C for 1 hr under an Ar atmosphere. After cooling, the reaction mixture was neutralized by passing it through an Amberlite IRA-93ZU (Organo) column and chromatographed on silica gel eluting with a gradient mixture of CHCl₃-MeOH (19:1; 1:1) to give an aglycone (**10b**) (5.1 mg) and a mixture of monosaccharides (9.5 mg). The monosaccharide mixture was suggested to contain glucose, fucose and rhamnose by direct TLC comparison with authentic samples. *R_f* (*n*-BuOH-Me₂CO-H₂O, 4:5:1): 0.62 (rhamnose); 0.52 (fucose); 0.36 (glucose). The mixture (2 mg) was diluted with H₂O (1 ml) and treated with (-)- α -methylbenzylamine (5 mg) and Na[BH₃CN] (8 mg) in EtOH (1 ml) at 40°C for 4 hr, followed by acetylation with Ac₂O (0.3 ml) in pyridine (0.3 ml). The reaction mixture was passed through a Sep-Pak C₁₈ cartridge (Waters) with H₂O-MeCN (4:1; 1:9, each 10 ml). The H₂O-MeCN (1:9) eluate fr. was further passed through a Toyopak IC-SP M cartridge (Tosoh) with EtOH (10 ml) to give a mixture of 1-[(*S*)-*N*-acetyl- α -methylbenzylamino]-1-deoxyalditol acetate derivatives of the monosaccharides [21, 22], which were then analyzed by HPLC under the following conditions: solvent, MeCN-H₂O (2:3); flow rate, 0.8 ml min⁻¹; detection, UV 230 nm. The derivatives of D-fucose, D-glucose and L-rhamnose were detected. *R_t* (min): 20.77 (D-fucose derivative); 24.22 (D-glucose derivative); 27.22 (L-rhamnose derivative).

Compound 11. Amorphous solid. $[\alpha]_D^{25} -37.5^\circ$ (MeOH; *c* 0.41). Negative-ion FAB-MS *m/z* 901 [M-H]⁻. IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3430 (OH), 2925 (CH). ¹H NMR (pyridine-*d*₅): δ 6.39 (1H, *br s*, 1''-H), 5.34 and 5.07 (each 1H, *br s*, 27-H₂), 4.91 (1H, *d*, *J* = 7.8 Hz, 1'''-H), 4.73 (1H, *d*, *J* = 7.7 Hz, 1'-H), 3.25 (3H, *s*, OMe), 1.76 (3H, *d*, *J* = 6.1 Hz, 6''-Me), 1.25 (3H, *s*, 19-Me), 1.12 (3H, *d*, *J* = 6.8 Hz, 21-Me), 0.83 (3H, *s*, 18-Me).

Enzymatic hydrolysis of 11. Compound **11** (45 mg)

Table 1. ¹³C NMR spectral data for compounds **10**, **10a**, **10b**, **11**, **11a**, **12**, **12a** and **13** in pyridine-*d*₅

C	10	10a	10b	11	11a	12	12a	13
1	81.0	81.1	74.1	80.4	80.5	80.2	80.3	81.8
2	35.5	35.6	41.4	35.0	35.1	33.5	33.6	34.7
3	65.9	65.9	66.3	65.8	65.8	71.2	71.2	75.0
4	37.4	37.4	37.1	37.3	37.3	69.9	69.9	74.6
5	39.4	39.4	38.9	39.4	39.4	45.6	45.6	49.8
6	28.8	28.8	28.9	28.8	28.8	23.1	23.1	22.9
7	32.6	32.7	32.8	32.6	32.6	32.4	32.4	32.4
8	36.6	36.7	36.2	36.4	36.5	36.4	36.5	36.2
9	55.3	55.3	55.8	55.0	55.0	55.5	55.5	55.5
10	42.6	42.6	43.1	42.6	42.6	42.6	42.6	42.6
11	23.7	23.8	24.9	23.7	23.8	23.3	23.3	23.3
12	40.6	40.8	40.9	40.7	40.8	40.6	40.7	40.6
13	40.7	40.5	40.5	40.6	40.3	40.8	40.4	40.7
14	57.0	57.1	56.9	56.8	56.9	57.0	57.1	56.8
15	32.3	32.4	32.4	32.3	32.3	32.3	32.3	32.4
16	81.5	81.5	81.4	81.4	81.4	81.5	81.5	81.5
17	64.3	63.2	63.3	64.3	63.2	64.3	63.1	64.3
18	16.9	17.0	16.8	16.7	16.8	16.9	16.9	16.8
19	7.7	7.7	6.5	7.7	7.7	9.0	9.0	10.1
20	40.4	41.9	41.9	40.4	41.9	40.4	41.9	40.4
21	16.0	14.8	15.0	16.1	14.9	16.0	14.8	16.0
22	112.4	109.4	109.4	112.4	109.4	112.4	109.4	112.4
23	31.5	33.2	33.2	31.5	33.1	31.5	33.1	31.5
24	28.1	29.0	29.0	28.0	28.9	28.0	28.9	28.0
25	146.8	144.5	144.5	146.8	144.5	146.8	144.5	146.8
26	72.0	65.0	65.0	72.0	64.9	72.0	64.9	72.0
27	111.0	108.6	108.6	111.0	108.6	111.0	108.6	111.0
OMe	47.3			47.3		47.3		47.3
1'	100.2	100.3		100.4	100.5	100.2	100.3	99.7
2'	74.3	74.3		74.9	74.9	74.3	74.3	73.9
3'	77.0	77.1		76.3	76.3	77.0	77.0	76.9
4'	73.3	73.3		70.3	70.3	73.3	73.3	73.3
5'	71.0	71.1		67.5	67.5	71.1	71.1	71.2
6'	17.1	17.1				17.1	17.1	17.1
1''	101.4	101.4		101.5	101.5	101.4	101.4	101.4
2''	72.6	72.6		72.6	72.5	72.6	72.6	72.5
3''	72.6	72.6		72.6	72.6	72.6	72.6	72.5
4''	74.3	74.3		74.2	74.2	74.3	74.3	74.2
5''	69.2	69.2		69.3	69.3	69.2	69.2	69.2
6''	19.0	19.0		19.0	19.0	19.0	19.0	19.0
1'''	103.8			103.8		103.8		103.8
2'''	75.1			75.1		75.1		75.1
3'''	78.6			78.6		78.6		78.6
4'''	71.7			71.7		71.7		71.7
5'''	78.5			78.5		78.5		78.5
6'''	62.8			62.8		62.8		62.8

was treated with β -glucosidase (100 mg) in HOAc-NaOAc buffer (pH 5, 10 ml) at room temp. for 48 hr. The reaction mixture was subjected to silica gel CC eluting with CHCl₃-MeOH (3:1) and prep. TLC with CHCl₃-MeOH-H₂O (30:10:1) to give the cor-

responding spirostanol saponin (**11a**) (21.5 mg) and glucose (5.1 mg).

Compound 11a. Amorphous solid. $[\alpha]_D^{29}$ –68.7° (MeOH; *c* 0.91). Positive-ion FAB-MS m/z 747 $[M+K]^+$. IR $\nu_{\max}^{\text{KBr}}$ cm^{-1} : 3420 (OH), 2920 (CH). ^1H NMR (pyridine- d_5): δ 6.39 (1H, *br s*, 1''-H), 4.81 and 4.77 (each 1H, *br s*, 27-H₂), 4.74 (1H, *d*, $J = 7.7$ Hz, 1'-H), 1.77 (3H, *d*, $J = 6.1$ Hz, 6''-Me), 1.26 (3H, *s*, 19-Me), 1.05 (3H, *d*, $J = 6.9$ Hz, 21-Me), 0.86 (3H, *s*, 18-Me).

Acid hydrolysis of 11. Compound **11** (10 mg) was subjected to acid hydrolysis as described for **10** to give an aglycone (**10b**) (2.5 mg) and a mixture of monosaccharides (5.7 mg). The monosaccharides were identified as D-xylose, L-arabinose and L-rhamnose by direct TLC comparison with authentic samples and HPLC analysis of their corresponding 1-[(*S*)-*N*-acetyl- α -methylbenzylamino]-1-deoxyalditol acetate derivatives. R_f (*n*-BuOH-Me₂CO-H₂O, 4:5:1): 0.64 (rhamnose); 0.48 (arabinose); 0.36 (glucose). R_t (min): 17.63 (L-arabinose derivative); 24.27 (D-glucose derivative); 27.22 (L-rhamnose derivative).

Compound 12. Amorphous solid. $[\alpha]_D^{29}$ –64.0° (MeOH; *c* 0.10). Negative-ion FAB-MS m/z 931 $[M-H]^-$. IR $\nu_{\max}^{\text{KBr}}$ cm^{-1} : 3420 (OH), 2915 (CH). ^1H NMR (pyridine- d_5): δ 6.41 (1H, *br s*, 1''-H), 5.34 and 5.05 (each 1H, *br s*, 27-H₂), 4.91 (1H, *d*, $J = 7.8$ Hz, 1'''-H), 4.78 (1H, *d*, $J = 7.7$ Hz, 1'-H), 4.49 (1H, *dd*, $J = 11.7$, 4.1 Hz, 1-H), 4.30 (1H, *br dd*, $J = 3.4$, 2.5 Hz, 3-H), 3.75 (1H, *dd*, $J = 10.9$, 2.5 Hz, 4-H), 3.25 (3H, *s*, OMe), 2.63 (1H, *ddd*, $J = 13.8$, 4.1, 3.4 Hz, 2eq-H), 2.29 (1H, *br dd*, $J = 13.8$, 11.7 Hz, 2ax-H), 2.00 (1H, *m*, 5-H), 1.74 (3H, *d*, $J = 6.1$ Hz, 6''-Me), 1.45 (3H, *d*, $J = 6.3$ Hz, 6'-Me), 1.33 (3H, *s*, 19-Me), 1.10 (3H, *d*, $J = 6.9$ Hz, 21-Me), 0.85 (3H, *s*, 18-Me).

Enzymatic hydrolysis of 12. Compound **12** (30 mg) was treated with β -glucosidase (50 mg) in HOAc-NaOAc buffer (pH 5, 5 ml) at room temp. for 24 hr. The reaction mixture was subjected to silica gel CC eluting with CHCl₃-MeOH-H₂O (25:10:1) to give the corresponding spirostanol saponin (**12a**) (17.8 mg) and glucose (4.9 mg).

Compound 12a. Amorphous solid. $[\alpha]_D^{23}$ –84.4° (MeOH; *c* 0.87). Negative-ion FAB-MS m/z 737 $[M-H]^-$. IR $\nu_{\max}^{\text{KBr}}$ cm^{-1} : 3420 (OH), 2910 (CH). ^1H NMR (pyridine- d_5): δ 6.41 (1H, *br s*, 1''-H), 4.87 (1H, *dq*, $J = 9.5$, 6.1 Hz, 5''-H), 4.80 (1H, *br s*, 27-Ha), 4.78 (1H, *d*, $J = 7.7$ Hz, 1'-H), 4.77 (2H, overlapping, 27-Hb and 2''-H), 4.62 (1H, *dd*, $J = 9.5$, 3.3 Hz, 3''-H), 4.53 (1H, *dd*, $J = 9.3$, 7.7 Hz, 2'-H), 4.50 (1H, *q*-like, $J = 7.4$ Hz, 16-H), 4.48 (1H, *dd*, $J = 11.7$, 4.2 Hz, 1-H), 4.45 and 4.01 (each 1H, *br d*, $J = 12.0$ Hz, 26-H₂), 4.32 (1H, *dd*, $J = 9.5$, 9.5 Hz, 4''-H), 4.30 (1H, *br dd*, $J = 3.5$, 2.4 Hz, 3-H), 4.09 (1H, *dd*, $J = 9.3$, 3.2 Hz, 3'-H), 3.87 (1H, *br d*, $J = 3.2$ Hz, 4'-H), 3.75 (1H, *dd*, $J = 10.9$, 2.4 Hz, 4-H), 3.56 (1H, *br q*, $J = 6.3$ Hz, 5'-H), 2.63 (1H, *ddd*, $J = 14.1$, 4.2, 3.5 Hz, 2eq-H), 2.31 (1H, *br dd*, $J = 14.1$, 11.7 Hz, 2ax-H), 2.00 (1H, *m*, 5-H), 1.75 (3H, *d*, $J = 6.1$ Hz, 6''-Me), 1.45 (3H, *d*,

$J = 6.3$ Hz, 6'-Me), 1.34 (3H, *s*, 19-Me), 1.02 (3H, *d*, $J = 6.9$ Hz, 21-Me), 0.88 (3H, *s*, 18-Me).

Compound 13. Amorphous solid. $[\alpha]_D^{29}$ –64.8° (MeOH; *c* 0.11). Negative-ion FAB-MS m/z 931 $[M-H]^-$. IR $\nu_{\max}^{\text{KBr}}$ cm^{-1} : 3425 (OH), 2915 (CH). ^1H NMR (pyridine- d_5): δ 6.40 (1H, *br s*, 1''-H), 5.34 and 5.05 (each 1H, *br s*, 27-H₂), 4.91 (1H, *d*, $J = 7.7$ Hz, 1'''-H), 4.78 (1H, *d*, $J = 7.8$ Hz, 1'-H), 4.05 (1H, *dd*, $J = 11.9$, 4.0 Hz, 1-H), 3.87 (1H, *ddd*, $J = 12.9$, 9.8, 5.0 Hz, 3-H), 3.73 (1H, *dd*, $J = 12.9$, 9.8 Hz, 4-H), 3.25 (3H, *s*, OMe), 2.79 (1H, *ddd*, $J = 12.9$, 5.0, 4.0 Hz, 2eq-H), 2.34 (1H, *ddd*, $J = 12.9$, 12.9, 11.9 Hz, 2ax-H), 1.73 (3H, *d*, $J = 6.1$ Hz, 6''-Me), 1.52 (3H, *d*, $J = 6.3$ Hz, 6'-Me), 1.33 (3H, *s*, 19-Me), 1.28 (1H, *m*, 5-H), 1.12 (3H, *d*, $J = 6.8$ Hz, 21-Me), 0.84 (3H, *s*, 18-Me).

Acknowledgments—We are grateful to Dr Y. Shida of the Central Analytical Center of Tokyo University of Pharmacy and Life Science for the measurements of the mass spectra.

REFERENCES

1. Mahato, S. B., Ganguly, A. N. and Sahu, N. P., *Phytochemistry*, 1982, **21**, 959.
2. Hostettman, K. and Marston, A., in *Saponins*, Cambridge University Press, London, 1995.
3. Takaashi, Y., Mimaki, Y., Kuroda, M., Sashida, Y., Nikaido, T. and Ohmoto, T., *Tetrahedron*, 1995, **51**, 2281.
4. Takaashi, Y., Mimaki, Y., Kameyama, A., Kuroda, M., Sashida, Y., Nikaido, T., Koike, K. and Ohmoto, T., *Chemical and Pharmaceutical Bulletin*, 1995, **43**, 1180.
5. Mimaki, Y., Takaashi, Y., Kuroda, M., Sashida, Y. and Nikaido, T., *Phytochemistry*, 1996, **42**, 1609.
6. Mimaki, Y., Inoue, T., Kuroda, M. and Sashida, Y., *Phytochemistry*, 1996, **43**, 1325.
7. Mimaki, Y., Inoue, T., Kuroda, M. and Sashida, Y., *Phytochemistry*, 1997, **44**, 107.
8. Mimaki, Y., Takaashi, Y., Kuroda, M. and Sashida, Y., *Phytochemistry*, 1997, **45**, 1229.
9. Mimaki, Y., Kuroda, M., Takaashi, Y. and Sashida, Y., *Phytochemistry*, 1998, **47**, 79.
10. Nakano, K., Murakami, K., Takaishi, Y., Tomimatsu, T. and Nohara, T., *Chemical and Pharmaceutical Bulletin*, 1989, **37**, 116.
11. Mahato, S. B., Sahu, N. P. and Ganguly, A. N., *Indian Journal of Chemistry*, 1980, **19B**, 817.
12. Ono, M., Shoyama, K. and Nohara, T., *Shoyakugaku Zasshi*, 1988, **42**, 135.
13. Watanabe, Y., Sanada, S., Ida, Y. and Shoji, J., *Chemical and Pharmaceutical Bulletin*, 1983, **31**, 3486.
14. Asano, T., Murayama, T., Hirai, Y. and Shoji, J., *Chemical and Pharmaceutical Bulletin*, 1993, **41**, 566.

15. Teshima, S., Kajimoto, T., Nakano, K., Tomimatsu, T., Yamasaki, M. and Nohara, T., *Chemical and Pharmaceutical Bulletin*, 1986, **34**, 3925.
16. Gupta, R. K., Jain, D. C. and Thakur, R. S., *Phytochemistry*, 1985, **24**, 2399.
17. Kiyosawa, S., Hutoh, M., Komori, T., Nohara, T., Hosokawa, I. and Kawasaki, T., *Chemical and Pharmaceutical Bulletin*, 1968, **16**, 1162.
18. Nohara, T., Miyahara, K. and Kawasaki, T., *Chemical and Pharmaceutical Bulletin*, 1975, **23**, 872.
19. Agrawal, P. K., Jain, D. C., Gupta, R. K. and Thakur, R. S., *Phytochemistry*, 1985, **24**, 2479.
20. Blunden, G., Jaffer, J. A., Jewers, K. and Griffin, W. J., *Tetrahedron*, 1981, **37**, 2911.
21. Oshima, R. and Kumanotani, J., *Chemistry Letters*, 1981, 943.
22. Oshima, R., Yamauchi, Y. and Kumanotani, J., *Carbohydrate Research*, 1982, **107**, 169.